Archemix

Archemix is a drug discovery and development company founded by experts in molecular biology and drug discovery, and backed by experienced biotech investors. Using proprietary technologies, we create biotherapeutics and drug discovery tools. Working independently and through alliances with pharmaceutical partners, we are committed to driving the science of making better medicines.

Contact Details: 1 Hampshire Street Cambridge MA United States of America Tel: (617) 621 700 Fax: (617) 225 6965 Email: info@archemix.com. WWW: www.archemix.com/

Recent Publications by Archemix:
Novel therapeutic modalities to address nondrugable protein interaction targets. Small molecule drugs are relatively effective in working on 'drugable'...	10th March, 2009	Archemix Corporation,	Neuropsychopharmacology. 2009 Jan;34(1):142-58. Epub 2008 Aug 27. DOI Direct Link
SELEX with modified nucleotides. Aptamers, a promising new class of therapeutics, are single-stranded...	8th January, 2009	Archemix Corp., 300 Third Street, Cambridge, MA 02142, USA.	Curr Opin Chem Biol. 2008 Aug;12(4):448-56. Epub 2008 Jul 21. DOI Direct Link
Predictive toxicogenomics in preclinical discovery. The failure of drug candidates during clinical trials due to toxicity,...	6th August, 2008	Toxicology, Archemix Corp., Cambridge, Massachusetts, USA.	Methods Mol Biol. 2008;460:89-112. DOI Direct Link
Aptamers as candidate therapeutics for cardiovascular indications. The first therapeutic aptamer was approved for human use in 2004, and a...	23rd July, 2008	Archemix Corporation, 300 Third Street, Cambridge, MA 02142, USA.	Curr Opin Pharmacol. 2008 Apr;8(2):147-52. Epub 2008 Jan 28. DOI Direct Link
Complex target SELEX. Aptamers are non-naturally occurring structured oligonucleotides that may...	29th May, 2008	Archemix Corporation, 300 Third Street, Cambridge, Massachusetts 02142,	Acc Chem Res. 2008 Jan;41(1):130-8. DOI Direct Link
→View more Archemix research publications.

Press Releases on Archemix:
Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009	6th August, 2009	Isis Pharmaceuticals, Inc.	-- Expand pipeline by moving at least two additional drugs into development in 2009; one new drug has already moved into development this year Financial Results On a GAAP basis, Isis
GEN Reports on Novel Hit-to-Lead Drug Discovery Strategies	8th July, 2008	Genetic Engineering and Biotechnology News	NEW ROCHELLE, N.Y., July 8 /PRNewswire/ -- Biotech and pharmaceutical firms are developing a host of new technologies designed to streamline the complicated drug discovery process, reports Genetic
Nuvelo Initiates Phase 1B Clinical Trial of Anticoagulant NU172	4th June, 2008	Nuvelo, Inc.	SAN CARLOS, Calif., June 4 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (Nasdaq: NUVO) today announced that it has enrolled the first patient in a single-center, Phase 1b trial to determine the safety,
The Board of International Biotechnology Trust Plc (“IBT”) today	1st May, 2005	International Biotechnology Trust	The Board of International Biotechnology Trust Plc (“IBT”) today announces its unaudited Annual Results for the twelve months ended 31 August 2005 Summary • Net asset value per share rose
ARCHEMIX APPOINTS STEVEN HOLTZMAN TO BOARD OF DIRECTORS	1st May, 2001	Archemix	ARCHEMIX APPOINTS STEVEN HOLTZMAN TO BOARD OF DIRECTORS CAMBRIDGE, MA — May 14, 2002 — Archemix Corporation, a privately held drug

Archemix Clinical Trials:
Effect of ARC1779 on Cerebral Microembolism in Patients Undergoing Carotid Endarterectomy

Archemix Patents:
US Patent No.	Title
7589073	Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
7579456	Aptamer therapeutics useful in the treatment of complement-related disorders
7579450	Nucleic acid ligands specific to immunoglobulin E and their use as atopic disease therapeutics
7566701	Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
7538211	Aptamer therapeutics useful in the treatment of complement-related disorders
→View more Archemix patents.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 586 times since April 2007, the link to the organisation's website has been followed 75 times

Recent Search Terms used to find this page: NU172 aptamer patent | archemix 2009 | archemix 2009 | archemix news | archemix pharmaceuticals | Archemix Corp email | archemix news | archemix news | archemix news | Nuvelo Inc. and NU172 and patent | .

Search for more companies in Cambridge

Search for more companies in MA

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Archemix